Echocardiography: Value and Accuracy at REst and STress

Summary

EVAREST will identify and validate novel blood and imaging biomarkers of potential value for consistent and accurate interpretation of stress echocardiography. During phase one, blood samples will be collected to assess the impact of cardiac stress on levels of circulating biomarkers and examine whether the measurement of these biomarkers can provide additional prognostic information. Phases one, two and three will also determine whether novel imaging biomarkers can be identified in the echocardiograms that can be used for objective interpretation of the stress echocardiograms. EVAREST will recruit up to 8000 patients (First 500 during phase one, an additional 500 during phase two and an additional 7000 during phase three) from multiple hospitals across United Kingdom, who have been referred for a stress echocardiogram as part of their investigations into ischaemic heart disease. Phase four of the study will continue into a clinical study cohort phase to capture information from all patients referred for a stress echocardiogram in the UK, regardless of the reason for investigation.This registry phase will run for 2 years, recruiting up to 15000 participants.

Conditions

• Coronary Artery Disease
• Ischaemic Heart Disease
• Angina Pectoris

Sponsors & Collaborators

• Oxford University Hospitals NHS Trust

  collaborator OTHER

• Royal United Hospital Bath NHS Trust

  collaborator OTHER

• Tameside Hospital NHS Foundation Trust

  collaborator OTHER

• Royal Berkshire NHS Foundation Trust

  collaborator OTHER_GOV

• East Lancashire Hospitals NHS Trust

  collaborator OTHER

• Bradford Teaching Hospitals NHS Foundation Trust

  collaborator OTHER_GOV

• Calderdale and Huddersfield NHS Foundation Trust

  collaborator OTHER

• Great Western Hospitals NHS Foundation Trust

  collaborator OTHER

• Mid Essex Hospital NHS Trust

  collaborator OTHER

• Buckinghamshire Healthcare NHS Trust

  collaborator OTHER

• Wrightington, Wigan and Leigh NHS Foundation Trust

  collaborator OTHER

• Chelsea and Westminster NHS Foundation Trust

  collaborator OTHER

• Milton Keynes University Hospital NHS Foundation Trust

  collaborator OTHER_GOV

• University Hospitals Bristol and Weston NHS Foundation Trust

  collaborator OTHER

• North Middlesex University Hospital

  collaborator OTHER

• Northumbria Healthcare NHS Foundation Trust

  collaborator OTHER

• London North West Healthcare NHS Trust

  collaborator OTHER

• St George's University Hospitals NHS Foundation Trust

  collaborator OTHER

• Ultromics Ltd

  collaborator INDUSTRY

• National Institute for Health Research, United Kingdom

  collaborator OTHER_GOV

• King's College Hospital NHS Trust

  collaborator OTHER

• Guy's and St Thomas' NHS Foundation Trust

  collaborator OTHER

• Poole Hospital NHS Foundation Trust

  collaborator OTHER

• Blackpool Teaching Hospitals NHS Foundation Trust

  collaborator OTHER

• Mid Yorkshire Teaching NHS Trust

  collaborator OTHER

• Northampton General Hospital NHS Trust

  collaborator OTHER

• North West Anglia NHS Foundation Trust

  collaborator UNKNOWN

• Yeovil District Hospital NHS Foundation Trust

  collaborator OTHER

• East Suffolk and North Essex NHS Foundation Trust

  collaborator OTHER

• Nottingham University Hospitals NHS Trust

  collaborator OTHER

• Hampshire Hospitals NHS Foundation Trust

  collaborator OTHER

• Lantheus Medical Imaging

  collaborator INDUSTRY

• University of Oxford

  lead OTHER

Principal Investigators

• Paul Leeson · Cardiovascular Clinical Research Facility, University of Oxford

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-03-31

Primary Completion

2021-03-31

Completion

2033-09-30